Enbrel Corporate

23:42 EDT 20th March 2019 | BioPortfolio


VLST Corporation discovers and develops novel therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company’s technology may have utility include multiple sclerosis, lupus, cardiovascular disease, diabetes and obesity. The company has already identified eight novel disease targets and is currently evaluating three of these targets for their therapeu...

Enbrel® (etanercept)

Enbrel® (etanercept) is a TNF inhibitor approved for the following indications: moderately to severely active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and psoriasis.


ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your d...

Quick Search


review and buy Enbrel market research data and corporate reports here